Generated by AI
Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing allosteric small molecule therapies for difficult-to-treat diseases. Its current research centers on neurodegenerative disorders and other conditions linked to protein misfolding, with a particular emphasis on Parkinson’s disease and select rare genetic diseases. The company’s lead candidate, GT-02287, is being evaluated for Parkinson’s disease and is part of a broader pipeline aimed at addressing underlying disease mechanisms rather than only managing symptoms. Gain Therapeutics also uses its Magellan drug discovery platform to identify novel allosteric binding sites and design proprietary compounds with the potential to modulate protein function. Headquartered in Bethesda, Maryland, Gain Therapeutics operates as a specialized player in precision medicine and computational drug discovery within the biotechnology sector.
Website4800 Montgomery Lane
Bethesda, MD, 20814
United States
The latest articles about GANX.
IAPRD late-breaking poster shows MDS-UPDRS motor scores remained stable compared to baseline recorded at study entry with no disease progression a...
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about GANX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.